Ovid Therapeutics (OVID) Capital Expenditures Growth (1y) (2017 - 2024)
Ovid Therapeutics (OVID) Capital Expenditures Growth (1y) (2017 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Ovid Therapeutics | 118.66 Mn | -36.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -137.14% |
| Jun 30, 2024 | 1,285.71% |
| Mar 31, 2024 | 35.71% |
| Dec 31, 2023 | -41.64% |
| Sep 30, 2023 | -67.74% |
| Jun 30, 2023 | -99.34% |
| Mar 31, 2023 | -53.69% |
| Dec 31, 2022 | -25.94% |
| Sep 30, 2022 | 76.55% |
| Jun 30, 2022 | 9,067.26% |
| Dec 31, 2021 | -9.05% |
| Sep 30, 2021 | -42.45% |
| Jun 30, 2021 | -59.62% |
| Dec 31, 2020 | 241.09% |
| Sep 30, 2020 | 2,028.87% |
| Jun 30, 2020 | 1,715.28% |
| Mar 31, 2020 | 791.17% |
| Dec 31, 2019 | 1,028.84% |
| Sep 30, 2019 | 99.29% |
| Jun 30, 2019 | -99.05% |